AGPUHIGH SIGNALRISK10-K

AGPU has undergone a fundamental business transformation, pivoting from AI-driven cancer therapy development to cybersecurity operations while experiencing substantial operational contraction.

The complete removal of the company's core AI oncology business description and biobank references, combined with new cybersecurity governance language, indicates a major strategic pivot that fundamentally alters the investment thesis. The elimination of going concern warnings suggests improved financial stability, but this dramatic business model shift creates significant uncertainty about future performance and competitive positioning in an entirely different industry sector.

Comparing 2026-03-31 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

The financial results reflect a company in transition, with revenue growing modestly while gross profit declined meaningfully and R&D expenses contracted substantially, suggesting reduced investment in product development. The dramatic reduction in accounts receivable and elimination of interest expense indicate improved working capital management and debt reduction. However, rising current liabilities alongside declining gross margins suggest operational pressures that may reflect the challenges of executing this business transformation.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-100%
$391K→3

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Accounts Receivable
Balance Sheet
-95.7%
$746K→$32K

Receivables declined — improved collection efficiency or conservative revenue recognition.

R&D Expense
P&L
-86.2%
$188K→$26K

R&D spending cut 86.2% — could signal cost discipline or concerning reduction in innovation investment.

Revenue
P&L
+43.4%
$456K→$655K

Strong top-line growth of 43.4% — accelerating demand or successful expansion into new markets.

Gross Profit
P&L
-30.4%
$1.1M→$798K

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Inventory
Balance Sheet
-22%
$494K→$386K

Inventory reduced 22% — lean inventory management or demand outpacing supply.

Current Liabilities
Balance Sheet
+18.7%
$3.6M→$4.3M

Current liabilities rose 18.7% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-31
ADDED
poai20251231_10k.htm FY 2025 --12-31 false 0001446159 2 2 0 0 0 0 0 5 5 10 3 5 5 5 5 5 0 10 10 0 0 0 15 0.01 0.01 0.01 0.01 false false false false The Senior Director of IT and Cybersecurity, in coordination with our executive officers, work collaboratively across the Company to implement a program designed to protect the Company s information systems from cybersecurity threats and to promptly respond to any cybersecurity incidents in accordance with the Company s incident response plan.
To facilitate the Company s cybersecurity risk management program, the Company s internal IT team is deployed to work with business functions across the Company to address cybersecurity threats and to respond to cybersecurity incidents.
The Senior Director of IT and Cybersecurity, as leader of the internal IT team, monitors the prevention, detection, mitigation, and remediation of cybersecurity threats and incidents in real time, and reports such threats and incidents to the executive officers and Board when appropriate.
The Board oversees the Company s ERM process, including the management of risks arising from cybersecurity threats.
The Board receives reports on cybersecurity risks, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological trends, and information security considerations arising with respect to the Company s peers and third parties.
+7 more — sign up free →
REMOVED
As of June 28, 2024, the last business day of the registrant s most recently completed second fiscal quarter, the aggregate market value of common stock held by non-affiliates was $ 5,819,537 based upon 5,595,709 shares at $1.04 per share as reported on the NASDAQ Capital Market.
As of March 26, 2025, the registrant had 8,931,621 shares of common stock, par value $.01 per share, outstanding.
The following summarizes the principal risks of our business: There is substantial doubt about our ability to continue as a going concern without additional financing; Risks relating to our plans regarding a merger with Renovaro, Inc.
General References in this annual report on Form 10-K to Predictive , Company , we , us , and our refer to the business of Predictive Oncology Inc.
Overview We are a knowledge and science-driven company that applies artificial intelligence ( AI ) to support the discovery and development of optimal cancer therapies, which can ultimately lead to more effective treatments and improved patient outcomes.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →